Gardnerella swidsinskii is one of several recently named species within the Gardnerella genus, a group of bacteria long treated as a single species and closely tied to bacterial vaginosis. Formally described in 2019 alongside Gardnerella leopoldii and Gardnerella piotii, G. swidsinskii carries its own set of virulence traits and metabolic quirks that distinguish it from other members of the genus. Its effects on vaginal health are still being untangled, but emerging research suggests that which Gardnerella species a person harbors matters more than whether Gardnerella is present at all.
From One Species to a Whole Genus
For decades, researchers lumped every Gardnerella isolate under the single name Gardnerella vaginalis. That changed in 2019 when a team analyzing 81 full genomes found that what had been called one species was actually at least 13 genetically distinct groups. Three of those groups were different enough to receive formal species names: G. leopoldii, G. piotii, and G. swidsinskii, while the original G. vaginalis designation was narrowed to cover only a specific subset of strains.1PubMed. Emended description of Gardnerella vaginalis and description of Gardnerella leopoldii sp. nov., Gardnerella piotii sp. nov. and Gardnerella swidsinskii sp. nov., with delineation of 13 genomic species within the genus Gardnerella This reclassification was not just a naming exercise. The different species carry different enzymes, form biofilms differently, and respond to antibiotics differently. Understanding which species is present in a given person’s vaginal microbiome turns out to be clinically relevant in ways the old one-species model could never capture.
Is G. swidsinskii Really Its Own Species?
The taxonomy here is still contested. A large-scale pangenome study published in Nature Communications found that while G. swidsinskii forms a well-supported branch on the Gardnerella family tree and can be distinguished by its traits, it does not quite cross the genomic thresholds typically used to call something a separate species. The standard cutoffs involve metrics that measure how similar two genomes are overall, and G. swidsinskii falls within the range of a broader species-level cluster rather than clearly outside it.2Nature Communications. A syntenic pangenome of Gardnerella reveals novel plasmids and phage, taxonomic boundaries, and species-level stratification of metabolic and virulence potential A separate pangenome analysis similarly concluded that the Gardnerella genus breaks into about six named species and eight additional genomic groups, broadly consistent with the earlier classification but leaving room for debate about where exactly the lines should be drawn.3bioRxiv. Unraveling the Gardnerella Pangenome: Insights into Genetic Diversity, Virulence, and Antibiotic Resistance
This matters for anyone reading the literature, because different research groups may lump G. swidsinskii into a broader genomic group or treat it as a standalone species depending on which taxonomic framework they follow. For clinical purposes, though, the practical question is less about naming conventions and more about whether the strains now called G. swidsinskii behave differently from other Gardnerella strains. The evidence suggests they do.
Gardnerella Is Almost Everywhere, but Not All Strains Cause Trouble
One of the most counterintuitive findings in vaginal microbiome research is how common Gardnerella is in healthy women. A study of women without bacterial vaginosis found Gardnerella in 87% of them.4PubMed Central. Prevalence and distribution of Gardnerella vaginalis subgroups in women with and without bacterial vaginosis That number alone should make it clear that simply detecting Gardnerella in a vaginal sample tells you very little about whether someone has or will develop BV.
The study, which used the older clade system that predated formal species names, found that the specific types of Gardnerella present mattered a great deal. Certain clades were strongly associated with high BV scores: clade 1 and clade 2 were far more common in women with full-blown BV, while clade 3 and clade 4 showed no meaningful association with disease.4PubMed Central. Prevalence and distribution of Gardnerella vaginalis subgroups in women with and without bacterial vaginosis Perhaps most telling, having multiple clades at once was independently associated with higher BV scores, suggesting that the diversity of Gardnerella types colonizing the vagina, not just their presence, pushes the microbial community toward dysbiosis.
How Gardnerella Species Build Biofilms
The hallmark of bacterial vaginosis is a dense biofilm coating the vaginal epithelium, and Gardnerella species are consistently found at the core of that biofilm. Research using fluorescence imaging to map the spatial arrangement of bacteria in BV biofilms has shown that Gardnerella species are abundant throughout the developing structure and act as scaffolding for other BV-associated organisms. Specifically, Gardnerella facilitates the incorporation of Fannyhessea vaginae (formerly Atopobium vaginae) at later stages of biofilm development, helping build the layered microbial community that makes BV so difficult to treat.5PubMed Central. Spatial organization of Gardnerella species, Prevotella bivia, and Fannyhessea vaginae in the bacterial vaginosis biofilm
What allows Gardnerella to anchor these biofilms? A key family of enzymes called sialidases plays a central role. These enzymes strip sialic acid from the surface of vaginal epithelial cells, which does several things at once: it provides a carbon source for bacterial growth, it exposes binding sites on the cell surface so bacteria can adhere more tightly, and it degrades the protective cervicovaginal mucus that normally acts as a physical barrier against infection.6PubMed Central. Slipped-Strand Mispairing in the Gene Encoding Sialidase NanH3 in Gardnerella spp. Sialidases also break down immunoglobulin A, a key antibody found in mucosal secretions, weakening the local immune defense.7Scientific Reports. Cervicovaginal Gardnerella sialidase-encoding gene in persistent human papillomavirus infection
Not every Gardnerella species carries the same sialidase toolkit, though. The gene for one particularly potent extracellular sialidase, called NanH3, is found almost exclusively in G. piotii and a closely related genomic species, and its presence reliably predicted sialidase activity in a collection of 112 isolates.6PubMed Central. Slipped-Strand Mispairing in the Gene Encoding Sialidase NanH3 in Gardnerella spp. That enzyme also undergoes a process called phase variation, where the gene switches on and off through random mutations during DNA replication. This may help those species evade the immune system by toggling their surface properties, making them harder targets for the body’s defenses.
What Makes G. swidsinskii Distinctive
While much of the biofilm and sialidase research points to G. piotii as the most overtly aggressive species, G. swidsinskii has its own features that set it apart. One is the presence of a surface enzyme called GAPDH, which among the named Gardnerella species is carried only by G. swidsinskii and G. leopoldii.8American Journal of Obstetrics & Gynecology. Gardnerella Species Variations Show Pathogenic and Metabolic Differences GAPDH is better known as a metabolic enzyme, but in pathogenic bacteria it moonlights as a surface protein that helps cells attach to host tissues and modulate immune responses. Its presence in G. swidsinskii and G. leopoldii, but not in other Gardnerella species, hints at a shared virulence strategy between these two lineages.
G. swidsinskii also stands out metabolically. All Gardnerella species carry a transport system for importing maltose and related sugars, but G. swidsinskii’s version of that system includes two sugar-binding proteins instead of the usual one. These two proteins share only about 60% similarity to each other, which means they likely recognize different sugars or bind the same sugar in different ways.9PubMed Central. Ligand-binding properties of substrate binding proteins of a maltose uptake system in Gardnerella swidsinskii Researchers have proposed that this doubled-up system could give G. swidsinskii a competitive edge over other Gardnerella species when carbohydrate resources are scarce in the vaginal environment. If G. swidsinskii can scavenge a broader range of sugars than its relatives, it may be better at persisting in microbial communities where nutrients are contested.
Another virulence factor worth noting across the genus is vaginolysin, a toxin that punches holes in human cells. A study comparing vaginolysin sequences from different Gardnerella species found that strains with the most common variant (Type 1) were more often associated with symptoms, while strains with a different variant (Type 2) tended to reach higher overall abundance in the vagina.10MDPI Pathogens / PubMed Central. Sequence Comparison of Vaginolysin from Different Gardnerella Species The amino acid differences between these variants appear to change how the toxin interacts with vaginal cells, which could help explain why some Gardnerella infections cause obvious symptoms while others fly under the radar.
Antibiotic Resistance Varies Dramatically by Species
Metronidazole is the standard first-line antibiotic for BV, and BV has notoriously high recurrence rates. The species-level diversity within Gardnerella offers a partial explanation for why. A study testing 60 Gardnerella isolates spanning ten genospecies found that 82% were resistant to metronidazole.11PubMed Central. Metronidazole response profiles of Gardnerella species are congruent with phylogenetic and comparative genomic analyses But the resistance was not evenly distributed. Certain genospecies were uniformly and highly resistant, with every single strain tested showing concentrations needed to kill them far above the clinical threshold. Others showed a mix of responses, with some strains killed at moderate doses and others requiring extremely high concentrations.
This pattern has direct clinical implications. If a woman’s BV is driven by a highly resistant genospecies, standard metronidazole treatment may suppress but not eliminate the Gardnerella population, setting the stage for recurrence. A study of women with recurrent BV found that G. swidsinskii, along with G. leopoldii and G. vaginalis, were all cultured from patients who experienced treatment failure. In some recurrent cases, isolates that were sensitive to metronidazole at the initial visit had become resistant by the time BV returned.12Open Forum Infectious Diseases. Resistance to Metronidazole of Gardnerella in Women with Recurrent Bacterial Vaginosis In women with persistent BV that never cleared, isolates were resistant at both time points. The fact that resistance can develop during or after treatment is alarming and suggests that incomplete eradication under antibiotic pressure selects for resistant survivors.
One bright spot: clindamycin, the other commonly used BV antibiotic, remained effective against every strain tested. All 63 isolates across all genospecies showed high sensitivity to clindamycin, with the concentrations needed to kill them far below the clinical threshold.11PubMed Central. Metronidazole response profiles of Gardnerella species are congruent with phylogenetic and comparative genomic analyses For clinicians managing recurrent BV, this species-level resistance data argues for reconsidering metronidazole as a default and potentially favoring clindamycin, especially in women whose BV keeps coming back.
Pregnancy Outcomes and Species-Specific Risks
BV has long been associated with spontaneous preterm birth, but the species-level reclassification of Gardnerella has allowed researchers to ask a more precise question: which Gardnerella species actually drive the risk? A study of pregnant women at high risk of recurrent preterm birth found a statistically significant association between G. leopoldii and spontaneous preterm birth, with roughly double the odds in women carrying G. leopoldii early in pregnancy compared to those who did not.13Heliyon. Vaginal microbiota and spontaneous preterm birth in pregnant women at high risk of recurrence The other Gardnerella species, including G. swidsinskii, did not show significant associations with preterm birth in that study.
This is a good example of why species-level distinctions within the genus matter clinically. Under the old one-species model, any Gardnerella detection in a pregnant woman’s vaginal sample would raise the same level of concern. The newer data suggests the risk is concentrated in specific lineages. G. swidsinskii shares some virulence traits with G. leopoldii, including the GAPDH surface protein, but the pregnancy data so far does not point to it as a standalone risk factor for preterm birth. Whether that changes as larger studies accumulate remains to be seen.
Detecting G. swidsinskii Is Harder Than You Might Expect
One reason our understanding of G. swidsinskii has lagged is that it is genuinely difficult to grow in a laboratory. A prospective study comparing two culture methods found that Gardnerella vaginalis and G. leopoldii/swidsinskii together were detected in about 29% of vaginal samples, but the detection rate depended heavily on how the cultures were incubated. Growing samples in a carbon-dioxide-enriched atmosphere, which is the more convenient method for most clinical labs, caught only about 67% of the Gardnerella that full anaerobic cultivation detected.14PubMed Central. Prospective study of vaginal samples for the detection of Gardnerella vaginalis and G. swidsinskii/leopoldii using Gardnerella agar in CO(2) and anaerobic atmospheres In other words, about a third of positive samples were being missed when labs used the easier method. Strict anaerobic cultivation on selective Gardnerella agar proved to be the better approach.
This detection gap matters because it means G. swidsinskii and G. leopoldii have probably been systematically undercounted in clinical studies that relied on standard culture techniques. Molecular methods like DNA sequencing can pick up these species regardless of culture conditions, but sequencing is not yet routine in most clinical settings. Until it is, the true prevalence and clinical impact of G. swidsinskii is likely being underestimated.
The Role of Lactobacillus in Keeping Gardnerella in Check
The vaginal microbiome in healthy individuals is typically dominated by Lactobacillus species, which produce lactic acid and hydrogen peroxide. These substances create an acidic, inhospitable environment for many BV-associated bacteria, including Gardnerella. Research examining how Lactobacillus crispatus and Lactobacillus rhamnosus interact with Gardnerella biofilms found that hydrogen peroxide and D-lactic acid were the primary compounds responsible for inhibiting biofilm formation.15PubMed Central. Regulatory Effects of Lactobacillus crispatus and Lactobacillus rhamnosus on the Formation and Composition of Gardnerella Biofilms Bacteriocins and other unidentified factors may also contribute, but the acid and peroxide combination appears to do most of the heavy lifting.
This is relevant to G. swidsinskii because its enhanced sugar-scavenging ability, via the dual-binding-protein transport system described earlier, may help it persist in environments where other Gardnerella species would struggle. If G. swidsinskii can metabolize a wider range of carbohydrates, it could potentially survive longer during the transition from a Lactobacillus-dominated community to a BV-associated one, or hold on more stubbornly when Lactobacillus levels begin to recover after treatment.
Emerging Therapeutic Approaches
Given the high rates of metronidazole resistance across Gardnerella species and the stubbornness of polymicrobial biofilms, researchers have been exploring alternatives to conventional antibiotics. Strategies currently under investigation include probiotics designed to replenish Lactobacillus populations, prebiotics that selectively feed beneficial bacteria, acidifying agents that lower vaginal pH, plant-based antimicrobials, vaginal microbiota transplantation from healthy donors, and phage endolysins, which are enzymes derived from viruses that infect bacteria and can break apart biofilms from the outside.16PubMed Central. Fighting polymicrobial biofilms in bacterial vaginosis
Most of these approaches are still in early stages. Phage endolysins, for instance, are attractive because they can be engineered to target specific bacterial species without harming Lactobacillus, but clinical trial data in humans is thin. Vaginal microbiota transplantation has generated excitement based on small case series, but standardization and safety protocols are still being developed. Probiotics are the most commercially available option and have some clinical support, though results are inconsistent across studies and formulations. The species-level understanding of Gardnerella that has emerged in recent years could eventually make these therapies more targeted. If clinicians can identify which Gardnerella species are driving a patient’s BV, they could in theory select treatments more likely to work against that particular strain’s resistance profile and virulence toolkit, rather than relying on the same broad-spectrum antibiotic for everyone.